This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bowel scope in colorectal cancer screening

Authoring team

Bowel scope screening is a new part of the NHS Bowel Cancer Screening Programme and is being rolled out across England from 2013

  • involves once - only flexible sigmoidoscopy for all men and women around the time of the 55th birthday
  • everyone will still be invited to take part in Faecal Occult Blood testing every two years from the age of 60y
  • anybody 55-59 can self-refer if their GP practice is live and they missed the invitation, the interested person should call 0800 707 60 60 to check their eligibility (1)

Risks of procedure:

  • minor rectal bleeding after the procedure may occur but about 1 in 3,000 have serious bleeding needing hospital admission
  • a very small risk of bowel perforation (about 1 in 30,000)

Benefits of bowel scope screening:

  • key benefit of bowel scope screening is prevention of colorectal cancer
    • bowel scope screening was found to reduce the incidence of colorectal cancer over 11 years' follow up from 5 in 300 to 3 in 300 in a UK randomised controlled trial
      • ie 2 cases of colorectal cancer are prevented for every 300 people screened
  • reduces colorectal cancer mortality
    • reduces colorectal cancer deaths over 11 years' follow up from 2 in 300 to 1 in 300
      • ie 1 colorectal cancer death is prevented for every 300 people screened

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.